L'epistassi nel morbo di Rendu-Weber-Osler. Ruolo della brachiterapia.

Translated title of the contribution: Epistaxis in Rendu-Weber-Osler disease. The role of brachytherapy

G. Turcato, G. B. Pizzi, R. Polico, M. Antonello, M. Busetto

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Rendu-Weber-Osler disease is a rare autosomic disorder. Its most common symptom is epistaxis with transitory periods of remission and of ingravescent exacerbation compromising normal daily activities and forcing the patient to give up his normal life-style for prolonged periods of time. Often it proves difficult to control the recurrent epistaxis and the treatments available today are not always totally satisfactory. The authors present the results obtained using endonasal brachytherapy in 8 patients (13 treatments) epistaxis stemming from previously diagnosed Rendu-Weber-Osler disease. Brachytherapy employs thin plastic tubes, positioned in the nostril with the heaviest epistaxis. These tubes are then filled with Iridum192. The total dose, prescribed against the reference isodose, strictly adjacent to the nasal fossae mucosa, was 30 Gy over a period ranging from two to four days (average 2.5 days). Four patients required a second treatment to the controlateral nostril as the symptoms returned after a period ranging from 36 to 60 months (average 47.1 months). Only one patient required a second treatment in the same nostril 9 years later. The episodes of epistaxis were scored by symptom severity on a scale from 0 to 5. Of the 13 treatments administered (mono and bilateral treatments), 12 can be considered satisfactory as the epistaxis was reduced from the initial pre-treatment score of 4-5 to 2 or less (5 were reduced to 0, 3 to 1 and 4 to 2). In only 1 case was the score 3. Remission of symptoms lasted for a period ranging from 11 to 108 months with an average of 51.6 months. No complications arose from the use of brachytherapy. Only one patient required embolization 3 years after the endonasal brachytherapy treatment.

Original languageItalian
Pages (from-to)513-516
Number of pages4
JournalActa Otorhinolaryngologica Italica
Volume16
Issue number6
Publication statusPublished - Dec 1996

Fingerprint

Hereditary Hemorrhagic Telangiectasia
Epistaxis
Brachytherapy
Therapeutics
Nasal Mucosa
Plastics
Life Style

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Turcato, G., Pizzi, G. B., Polico, R., Antonello, M., & Busetto, M. (1996). L'epistassi nel morbo di Rendu-Weber-Osler. Ruolo della brachiterapia. Acta Otorhinolaryngologica Italica, 16(6), 513-516.

L'epistassi nel morbo di Rendu-Weber-Osler. Ruolo della brachiterapia. / Turcato, G.; Pizzi, G. B.; Polico, R.; Antonello, M.; Busetto, M.

In: Acta Otorhinolaryngologica Italica, Vol. 16, No. 6, 12.1996, p. 513-516.

Research output: Contribution to journalArticle

Turcato, G, Pizzi, GB, Polico, R, Antonello, M & Busetto, M 1996, 'L'epistassi nel morbo di Rendu-Weber-Osler. Ruolo della brachiterapia.', Acta Otorhinolaryngologica Italica, vol. 16, no. 6, pp. 513-516.
Turcato G, Pizzi GB, Polico R, Antonello M, Busetto M. L'epistassi nel morbo di Rendu-Weber-Osler. Ruolo della brachiterapia. Acta Otorhinolaryngologica Italica. 1996 Dec;16(6):513-516.
Turcato, G. ; Pizzi, G. B. ; Polico, R. ; Antonello, M. ; Busetto, M. / L'epistassi nel morbo di Rendu-Weber-Osler. Ruolo della brachiterapia. In: Acta Otorhinolaryngologica Italica. 1996 ; Vol. 16, No. 6. pp. 513-516.
@article{7e2d5da32c7840198e795732dbe1ee3a,
title = "L'epistassi nel morbo di Rendu-Weber-Osler. Ruolo della brachiterapia.",
abstract = "Rendu-Weber-Osler disease is a rare autosomic disorder. Its most common symptom is epistaxis with transitory periods of remission and of ingravescent exacerbation compromising normal daily activities and forcing the patient to give up his normal life-style for prolonged periods of time. Often it proves difficult to control the recurrent epistaxis and the treatments available today are not always totally satisfactory. The authors present the results obtained using endonasal brachytherapy in 8 patients (13 treatments) epistaxis stemming from previously diagnosed Rendu-Weber-Osler disease. Brachytherapy employs thin plastic tubes, positioned in the nostril with the heaviest epistaxis. These tubes are then filled with Iridum192. The total dose, prescribed against the reference isodose, strictly adjacent to the nasal fossae mucosa, was 30 Gy over a period ranging from two to four days (average 2.5 days). Four patients required a second treatment to the controlateral nostril as the symptoms returned after a period ranging from 36 to 60 months (average 47.1 months). Only one patient required a second treatment in the same nostril 9 years later. The episodes of epistaxis were scored by symptom severity on a scale from 0 to 5. Of the 13 treatments administered (mono and bilateral treatments), 12 can be considered satisfactory as the epistaxis was reduced from the initial pre-treatment score of 4-5 to 2 or less (5 were reduced to 0, 3 to 1 and 4 to 2). In only 1 case was the score 3. Remission of symptoms lasted for a period ranging from 11 to 108 months with an average of 51.6 months. No complications arose from the use of brachytherapy. Only one patient required embolization 3 years after the endonasal brachytherapy treatment.",
author = "G. Turcato and Pizzi, {G. B.} and R. Polico and M. Antonello and M. Busetto",
year = "1996",
month = "12",
language = "Italian",
volume = "16",
pages = "513--516",
journal = "Acta Otorhinolaryngologica Italica",
issn = "0392-100X",
publisher = "Pacini Editore s.r.l.",
number = "6",

}

TY - JOUR

T1 - L'epistassi nel morbo di Rendu-Weber-Osler. Ruolo della brachiterapia.

AU - Turcato, G.

AU - Pizzi, G. B.

AU - Polico, R.

AU - Antonello, M.

AU - Busetto, M.

PY - 1996/12

Y1 - 1996/12

N2 - Rendu-Weber-Osler disease is a rare autosomic disorder. Its most common symptom is epistaxis with transitory periods of remission and of ingravescent exacerbation compromising normal daily activities and forcing the patient to give up his normal life-style for prolonged periods of time. Often it proves difficult to control the recurrent epistaxis and the treatments available today are not always totally satisfactory. The authors present the results obtained using endonasal brachytherapy in 8 patients (13 treatments) epistaxis stemming from previously diagnosed Rendu-Weber-Osler disease. Brachytherapy employs thin plastic tubes, positioned in the nostril with the heaviest epistaxis. These tubes are then filled with Iridum192. The total dose, prescribed against the reference isodose, strictly adjacent to the nasal fossae mucosa, was 30 Gy over a period ranging from two to four days (average 2.5 days). Four patients required a second treatment to the controlateral nostril as the symptoms returned after a period ranging from 36 to 60 months (average 47.1 months). Only one patient required a second treatment in the same nostril 9 years later. The episodes of epistaxis were scored by symptom severity on a scale from 0 to 5. Of the 13 treatments administered (mono and bilateral treatments), 12 can be considered satisfactory as the epistaxis was reduced from the initial pre-treatment score of 4-5 to 2 or less (5 were reduced to 0, 3 to 1 and 4 to 2). In only 1 case was the score 3. Remission of symptoms lasted for a period ranging from 11 to 108 months with an average of 51.6 months. No complications arose from the use of brachytherapy. Only one patient required embolization 3 years after the endonasal brachytherapy treatment.

AB - Rendu-Weber-Osler disease is a rare autosomic disorder. Its most common symptom is epistaxis with transitory periods of remission and of ingravescent exacerbation compromising normal daily activities and forcing the patient to give up his normal life-style for prolonged periods of time. Often it proves difficult to control the recurrent epistaxis and the treatments available today are not always totally satisfactory. The authors present the results obtained using endonasal brachytherapy in 8 patients (13 treatments) epistaxis stemming from previously diagnosed Rendu-Weber-Osler disease. Brachytherapy employs thin plastic tubes, positioned in the nostril with the heaviest epistaxis. These tubes are then filled with Iridum192. The total dose, prescribed against the reference isodose, strictly adjacent to the nasal fossae mucosa, was 30 Gy over a period ranging from two to four days (average 2.5 days). Four patients required a second treatment to the controlateral nostril as the symptoms returned after a period ranging from 36 to 60 months (average 47.1 months). Only one patient required a second treatment in the same nostril 9 years later. The episodes of epistaxis were scored by symptom severity on a scale from 0 to 5. Of the 13 treatments administered (mono and bilateral treatments), 12 can be considered satisfactory as the epistaxis was reduced from the initial pre-treatment score of 4-5 to 2 or less (5 were reduced to 0, 3 to 1 and 4 to 2). In only 1 case was the score 3. Remission of symptoms lasted for a period ranging from 11 to 108 months with an average of 51.6 months. No complications arose from the use of brachytherapy. Only one patient required embolization 3 years after the endonasal brachytherapy treatment.

UR - http://www.scopus.com/inward/record.url?scp=0030322655&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030322655&partnerID=8YFLogxK

M3 - Articolo

VL - 16

SP - 513

EP - 516

JO - Acta Otorhinolaryngologica Italica

JF - Acta Otorhinolaryngologica Italica

SN - 0392-100X

IS - 6

ER -